<DOC>
	<DOCNO>NCT01202721</DOCNO>
	<brief_summary>The purpose study determine whether long-term treatment beta-blocker ( BB ) atenolol and/or angiotensin receptor blocker ( ARB ) telmisartan , give adult patient bicuspid aortic valve ( BAV ) disease ( aortopathy ) reduces widen ( dilatation ) aorta baseline size .</brief_summary>
	<brief_title>Beta Blockers Angiotensin Receptor Blockers Bicuspid Aortic Valve Disease Aortopathy ( BAV Study )</brief_title>
	<detailed_description>Bicuspid aortic valve ( BAV ) common congenital heart disease lesion estimate 280 000 560 000 people affect Canada . Dilatation ascend aorta common feature patient BAV result inherent vascular abnormality superimpose effect age acquire cardiovascular risk factor . Severe aortic dilatation ( &gt; 50mm ) lead aortic dissection premature death . Histopathological study aortas patient BAVs report similar finding patient Marfan syndrome . Beta Blocker ( BB ) therapy recently , Angiotensin Receptor Blocker ( ARB ) therapy , show decrease rate aortic dilatation benefit patient Marfan syndrome . There data however patient BAV aortopathy . Within context randomized clinical trial , investigator propose test hypothesis BB ARB reduce rate progressive aortic dilatation adult BAVs ascend aortopathy compare placebo . Design : Multicentre , randomize , double-blind , placebo-controlled , trial adult patient bicuspid aortic valve aortopathy . Patients eligible take either study medication randomly allocate participate either BB ( atenolol ) vs. placebo arm , ARB ( telmisartan ) vs. placebo arm . Patients ineligible BB arm assign ARB vs. placebo arm patient ineligible ARB arm assign BB vs. placebo arm . Within arm , participant randomize take either placebo active medication . The atenolol arm up-titrated to100mg/day telmisartan arm up-titrated 80 mg/day , maximum tolerate dose .</detailed_description>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Age = &gt; 18 year Men woman BAV ascend aorta measure &gt; 37mm . Written inform consent General Study Exclusion Criteria 1 . History cardiac disease , Symptomatic aortic stenosis aortic regurgitation refer surgical intervention asymptomatic severe aortic stenosis regurgitation base current guideline Uncontrolled heart failure , right ventricular failure due pulmonary hypertension Cardiogenic shock 2 . Systolic blood pressure &lt; 100 mmHg 3 . History drug sensitivity , contraindication adverse reaction BB ARB . Participants able tolerate BB allocate BB vs. placebo arm , participant able tolerate ARB allocate ARB vs. placebo arm , assume exclusion criterion meet . 4 . Ascending aorta measure â‰¥ 50mm , require prophylactic ascend aorta surgery 5 . Unable provide inform consent 6 . Need BB ARB treatment concomitant medical condition alternative . Participants take ARB discontinue allocate BB arm , participant take BB discontinue allocate ARB arm , exclusion criterion meet . 7 . Prior surgery ascend aorta aortic root ( balloon valvuloplasty , aortic valvotomy post coarctation surgery acceptable ) 8 . Women pregnant screen visit 9 . Contraindication MRI ( claustrophobia , pacemaker , metallic clip eye brain ) 10 . History illness limit participant ' ability complete study Additional Exclusion Criteria BB arm 1 . Heart rate &lt; 60 bpm 2 . Heart block ( 1st , 2nd 3rd degree AV block ECG ) , sick sinus syndrome 3 . Asthma sufficient severity represent contraindication BB use judgment patient 's physician 4 . History severe peripheral artery disorder 5 . History pheochromocytoma without use alphaadrenergic blocker 6 . History metabolic acidosis Additional Exclusion Criteria ARB arm 1 . Women pregnant , lactate intend become pregnant course study 2 . Women childbearing age reliable , accepted form birth control 3 . Hyperkalemia [ serum potassium &gt; 5.5 mmol/L ] renal dysfunction [ GFR &lt; 45 % measure MDRD ) 4 . Patients treat ACE Inhibitor discontinue . ( These patient may randomize BB arm exclusion criterion meet . ) 5 . History bilateral renal artery stenosis unilateral renal artery stenosis solitary kidney 6 . History hepatic insufficiency hepatobiliary obstruction 7 . History fructose intolerance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Congenital</keyword>
	<keyword>Aortic Valve</keyword>
	<keyword>Bicuspid</keyword>
	<keyword>Aortopathy</keyword>
	<keyword>bicuspid aortic valve aortopathy</keyword>
</DOC>